Windtree Therapeutics Files 8-K Report
Ticker: WINTW · Form: 8-K · Filed: Jul 3, 2024 · CIK: 946486
| Field | Detail |
|---|---|
| Company | Windtree Therapeutics Inc /De/ (WINTW) |
| Form Type | 8-K |
| Filed Date | Jul 3, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, 8-K
TL;DR
Windtree Therapeutics filed a routine 8-K, no major news.
AI Summary
On July 3, 2024, Windtree Therapeutics, Inc. filed an 8-K report. The filing primarily serves as a notification of a corporate action or event, with no specific financial transactions or material business developments detailed in the provided excerpt. The company, formerly known as Discovery Laboratories Inc., is incorporated in Delaware and headquartered in Warrington, Pennsylvania.
Why It Matters
This 8-K filing indicates a routine corporate update or disclosure, suggesting no immediate significant financial or operational changes for Windtree Therapeutics.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report without specific material events, indicating low immediate risk.
Key Numbers
- 001-39290 — Commission File Number (Identifies the company's filing with the SEC)
- 94-3171943 — I.R.S. Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Windtree Therapeutics, Inc. (company) — Registrant
- Discovery Laboratories Inc. (company) — Former company name
- July 3, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Warrington, Pennsylvania (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Windtree Therapeutics?
The primary purpose of this 8-K filing is to report a current event or corporate action, as indicated by the 'CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934' designation.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on July 3, 2024.
In which state is Windtree Therapeutics, Inc. incorporated?
Windtree Therapeutics, Inc. is incorporated in Delaware.
What is the address of Windtree Therapeutics' principal executive offices?
The principal executive offices of Windtree Therapeutics are located at 2600 Kelly Road, Suite 100, Warrington, Pennsylvania 18976.
What were some of Windtree Therapeutics' former company names?
Windtree Therapeutics was formerly known as Discovery Laboratories Inc. /DE/, Ansan Pharmaceuticals Inc., and Ansan Inc.
Filing Stats: 526 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-07-03 09:11:43
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share WINT The Nasdaq Capital Ma
Filing Documents
- wint20240703_8k.htm (8-K) — 25KB
- ex_695345.htm (EX-99.1) — 19KB
- slide01.jpg (GRAPHIC) — 110KB
- slide02.jpg (GRAPHIC) — 340KB
- slide03.jpg (GRAPHIC) — 258KB
- slide04.jpg (GRAPHIC) — 209KB
- slide05.jpg (GRAPHIC) — 238KB
- slide06.jpg (GRAPHIC) — 153KB
- slide07.jpg (GRAPHIC) — 115KB
- slide08.jpg (GRAPHIC) — 187KB
- slide09.jpg (GRAPHIC) — 197KB
- slide10.jpg (GRAPHIC) — 117KB
- slide11.jpg (GRAPHIC) — 157KB
- slide12.jpg (GRAPHIC) — 149KB
- slide13.jpg (GRAPHIC) — 145KB
- slide14.jpg (GRAPHIC) — 109KB
- slide15.jpg (GRAPHIC) — 165KB
- slide16.jpg (GRAPHIC) — 98KB
- slide17.jpg (GRAPHIC) — 121KB
- slide18.jpg (GRAPHIC) — 138KB
- slide19.jpg (GRAPHIC) — 114KB
- slide20.jpg (GRAPHIC) — 146KB
- slide21.jpg (GRAPHIC) — 172KB
- slide22.jpg (GRAPHIC) — 163KB
- slide23.jpg (GRAPHIC) — 188KB
- slide24.jpg (GRAPHIC) — 104KB
- slide25.jpg (GRAPHIC) — 159KB
- slide26.jpg (GRAPHIC) — 178KB
- slide27.jpg (GRAPHIC) — 68KB
- slide28.jpg (GRAPHIC) — 258KB
- slide29.jpg (GRAPHIC) — 232KB
- slide30.jpg (GRAPHIC) — 265KB
- slide31.jpg (GRAPHIC) — 185KB
- slide32.jpg (GRAPHIC) — 251KB
- 0001437749-24-022078.txt ( ) — 7738KB
- wint-20240703.xsd (EX-101.SCH) — 3KB
- wint-20240703_def.xml (EX-101.DEF) — 12KB
- wint-20240703_lab.xml (EX-101.LAB) — 15KB
- wint-20240703_pre.xml (EX-101.PRE) — 12KB
- wint20240703_8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. On July 3, 2024, the Company updated information reflected in a slide presentation, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the updated presentation in various meetings with investors from time to time. The information contained in this Item 7.01 (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section and shall not be deemed to be incorporated by reference in any filing under the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits The following exhibits are being filed herewith: Exhibit No. Document 99.1 Investor Presentation of Windtree Therapeutics, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: July 3, 2024 Windtree Therapeutics, Inc. By: /s/ Craig E. Fraser Name: Craig E. Fraser Title: President and Chief Executive Officer